NASDAQ:MPLT Maplight Therapeutics (MPLT) Stock Price, News & Analysis $13.15 +0.15 (+1.15%) Closing price 04:00 PM EasternExtended Trading$13.06 -0.09 (-0.71%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Maplight Therapeutics Stock (NASDAQ:MPLT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Maplight Therapeutics alerts:Sign Up Key Stats Today's Range$12.66▼$13.4550-Day Range$9.90▼$39.8052-Week Range$9.10▼$40.43Volume327,555 shsAverage Volume578,794 shsMarket Capitalization$609.90 millionP/E RatioN/ADividend YieldN/APrice Target$29.50Consensus RatingModerate Buy Company Overview MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for disorders of the central nervous system. The company’s research programs are aimed at addressing significant unmet needs in psychiatric and neurological diseases. MapLight’s pipeline consists of investigational therapies designed to target biological pathways associated with conditions such as schizophrenia and other brain disorders. Its activities include drug discovery, clinical development and the evaluation of potential treatments through clinical trials. The company’s products remain investigational and require successful clinical testing and regulatory review before they can be marketed. Publicly available information about MapLight Therapeutics’ broader commercial operations, geographic reach and leadership is limited.AI Generated. May Contain Errors. Read More Maplight Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreMPLT MarketRank™: Maplight Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 446th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingMaplight Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 4 strong buy ratings, 9 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialMaplight Therapeutics has a consensus price target of $29.50, representing about 124.3% upside from its current price of $13.15.Amount of Analyst CoverageMaplight Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Maplight Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Maplight Therapeutics are expected to grow in the coming year, from ($5.12) to ($4.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maplight Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maplight Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaplight Therapeutics has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.68% of the float of Maplight Therapeutics has been sold short.Short Interest Ratio / Days to CoverMaplight Therapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Maplight Therapeutics has recently increased by 5.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaplight Therapeutics does not currently pay a dividend.Dividend GrowthMaplight Therapeutics does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment0.93 News SentimentMaplight Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Maplight Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for MPLT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Maplight Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Maplight Therapeutics insiders have sold 86.22% more of their company's stock than they have bought. Specifically, they have bought $148,702.00 in company stock and sold $276,908.00 in company stock.Percentage Held by Insiders3.80% of the stock of Maplight Therapeutics is held by insiders.Percentage Held by InstitutionsMaplight Therapeutics has minimal institutional ownership at this time.Read more about Maplight Therapeutics' insider trading history. Receive MPLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maplight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MPLT Stock News HeadlinesMapLight Therapeutics to Participate in Upcoming Investor ConferenceSeptember 9, 2026 | globenewswire.comMapLight Therapeutics Launching $150 Million Private Placement FinancingAugust 13, 2026 | finance.yahoo.com“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI company holding 150 patents for technology that processes information up to 1,000 times faster than standard AI. Wall Street projects the company's sales to more than triple in the coming year, and Brown notes it's roughly the same size Nvidia was a decade ago, with a key catalyst set for November 11.September 14 at 1:00 AM | Brownstone Research (Ad)MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 13, 2026 | globenewswire.comMapLight Therapeutics Announces $150 Million Private Placement FinancingAugust 13, 2026 | globenewswire.comMapLight Therapeutics, Inc. (MPLT)August 11, 2026 | finance.yahoo.comMPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS LawAugust 3, 2026 | prnewswire.comMapLight Therapeutics, Inc. (MPLT) Gets a Buy from JefferiesJuly 31, 2026 | theglobeandmail.comSee More Headlines MPLT Stock Analysis - Frequently Asked Questions How have MPLT shares performed this year? Maplight Therapeutics' stock was trading at $17.57 at the start of the year. Since then, MPLT shares have decreased by 25.2% and is now trading at $13.15. How were Maplight Therapeutics' earnings last quarter? Maplight Therapeutics, Inc. (NASDAQ:MPLT) released its quarterly earnings data on Thursday, August, 13th. The company reported ($1.32) earnings per share for the quarter, topping analysts' consensus estimates of ($1.40) by $0.08. When did Maplight Therapeutics IPO? Maplight Therapeutics (MPLT) raised $252 million in an initial public offering on the week of October 27th 2025. The company issued 14,800,000 shares at a price of $17.00 per share. Morgan Stanley, Jefferies, Leerink and Stifel acted as the underwriters for the IPO. Who are Maplight Therapeutics' major shareholders? Top institutional shareholders of Maplight Therapeutics include BlackRock Inc. (2.41%), Nan Fung Group Holdings Ltd (2.28%), 5AM Venture Management LLC (2.23%) and Blue Owl Capital Holdings LP (1.71%). Insiders that own company stock include Christopher A Kroeger, Vishwas Setia, Erin Pennock Foff, Robert C Malenka, Anatol Kreitzer, James Woodruff Lillie, Jonathan Gillis, George Pavlov, Troy Cox and Timothy John Garnett. View institutional ownership trends. How do I buy shares of Maplight Therapeutics? Shares of MPLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today9/14/2026Morgan Stanley 24th Annual Global Healthcare Conference9/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MPLT CIK1770069 Webmaplightrx.com Phone(650) 839-4360FaxN/AEmployees133Year Founded2018Price Target and Rating Average Price Target for Maplight Therapeutics$29.50 High Price Target$46.00 Low Price Target$13.00 Potential Upside/Downside+124.3%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($42.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$161.15 million Net MarginsN/A Pretax MarginN/A Return on Equity-98.60% Return on Assets-60.33% Debt Debt-to-Equity RatioN/A Current Ratio16.52 Quick Ratio16.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.10 per share Price / Book1.30Miscellaneous Outstanding Shares46,380,000Free Float44,616,000Market Cap$609.90 million OptionableN/A BetaN/A Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:MPLT) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersYour backdoor link (still works)Bill Poulos is offering a private link to download his book Simple Options Trading For Beginners, bypassing th...Profits Run | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredGold just passed our debt as the world's #1 assetChina's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredI don't write about politics. Until today.Polls have favored a House flip all summer, and forecasters now expect Washington to change hands in November....American Alternative | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maplight Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maplight Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
